Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study

Respiratory Research

Table 3 Association of DHEAS in the lowest quartile with pulmonary function and survival in the validation cohort (men and women with fibrotic ILD)

DHEAS Lowest quartile	Unadjusted		Adjusted for
	Unadjusted		Age and sex		Age, sex, IPF and prednisone treatment
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
FVC, %	0.97 (0.95–0.99)	< 0.001	0.96 (0.94–0.98)	< 0.001	0.97 (0.95–0.99)	0.004
DLCO, %	0.97 (0.95–0.99)	0.008	0.97 (0.95–0.99)	0.004	0.97 (0.95–0.99)	0.02
CPI	1.03 (1.00–1.05)	0.03	1.03 (1.01–1.06)	0.01	1.03 (1.00–1.06)	0.08

	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Survival^a	1.96 (0.93–4.11)	0.07	2.30 (1.06–5.00)	0.03	3.17 (1.35–7.44)	0.008

E.g. every one % increase in FVC, %-predicted is associated with a 3% lower odds of a serum DHEAS value in the lowest quartile
CI confidence interval, CPI composite physiologic index, DHEAS dehydroepiandrosterone sulfate, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, HR hazard ratio, ILD interstitial lung disease, OR odds ratio
^aTime to death or lung transplantation e.g. patients with DHEAS in the lowest quartile have a 1.96 higher hazard for early death or lung transplant compared to those with normal/high DHEAS

ISSN: 1465-993X